Insilico Medicine has launched a Phase III clinical trial for Rentosertib, an innovative oral TNIK inhibitor aimed at treating idiopathic pulmonary fibrosis (IPF), utilizing its advanced Pharma.AI platform for drug discovery.
The trial marks a significant milestone for Insilico Medicine, as Rentosertib—previously referred to as ISM001-055 / INS018_055—targets TNIK, a protein linked to fibrosis and inflammation. This drug was developed through a combination of Insilico's PandaOmics biology engine and its Chemistry42 generative chemistry platform, showcasing the potential of AI-driven drug design. The initiation of this Phase III study follows promising preclinical and Phase IIa clinical data, which have been highlighted in notable scientific publications.
The upcoming trial aims to enroll 320 patients with IPF in China, where participants will receive Rentosertib daily for 52 weeks to evaluate its safety and efficacy. Led by Professor Zuojun Xu and a team of prominent researchers, the study seeks to build on the encouraging trends observed in earlier trials and aims for a rigorous assessment of the drug's potential benefits.
IPF is characterized by progressive lung scarring, and current treatments only slow its progression without reversing damage. The identification of TNIK as a therapeutic target through AI analysis underscores the transformative role of technology in addressing unmet medical needs. As Dr. Feng Ren from Insilico highlighted, Rentosertib's development stems from a biology-first approach, linking age-related mechanisms to disease pathways, which could pave the way for future AI-designed therapeutics in clinical settings.